Deteriorating profitability and impairment at petrochemical and materials facilities
First written in FY2016. 17 of 36 entries say "Materialised", first in FY2016. Latest entry: FY2027-H1.
Mitsubishi Chemical Group moved to the "Worse" side of this theme in 2016.
1 other company's latest entry also says "Mitigated".
- FY2027-H1MitigatedAnnual report
「No individually material impairment losses were recognized during the interim consolidated accounting period.」
The disclosure states that no individually material impairment losses were recognized for FY2027-H1. However, it does not state that the risk of impairment itself arising from deteriorating profitability in facilities and businesses had disappeared. - FY2026WorsenedAnnual report
「For the consolidated fiscal year, impairment losses of ¥98,458 million were recognized and included in “Other operating expenses” in the consolidated statement of income.」
Impairment losses increased from ¥94,576 million in the previous fiscal year to ¥98,458 million. Impairment losses were recognized on Soarnol facilities, coke and carbon-material facilities, J-Film, MMA facilities, ethylene oxide and ethylene glycol facilities and other assets. - FY2026-H1MaterialisedAnnual report
「As part of its portfolio transformation, the Group decided to transfer all shares of its consolidated subsidiary J-Film Co., Ltd. In connection with the transfer of assets held for sale based on this decision, a loss was recognized for the difference between fair value less costs to sell and carrying value. The carrying value of non-current assets, including equipment, of the company was reduced to their recoverable amount of ¥3,515 million, and impairment losses of ¥6,089 million were recognized, comprising ¥2,336 million for land, ¥2,049 million for buildings and ¥1,704 million for other assets.」
Impairment losses arising from deteriorating profitability in facilities and businesses and portfolio transformation actually materialized as impairment losses of ¥6,089 million related to the decision to transfer J-Film. In addition, impairment losses of ¥4,408 million were recognized in connection with the closure of the organic photoconductor business site in Vietnam. - FY2025WorsenedAnnual report
「For the consolidated fiscal year, impairment losses of ¥94,576 million were recognized and included in “Other operating expenses” in the consolidated statement of income.」
Impairment losses increased substantially from ¥33,530 million in the previous fiscal year to ¥94,576 million. Impairment losses were recognized on Soarnol facilities, Jerest, a new MMA plant in the United States, coke production facilities, carbon fiber-related facilities, semiconductor cleaning sites and other assets. - FY2025-H1WorsenedAnnual report
「During the interim consolidated accounting period, the company recorded impairment losses of ¥30,404 million.」
Impairment losses increased from ¥3,413 million in the same period of the previous year to ¥30,404 million. Impairment losses were recognized on hydrogen production facilities of ¥10,758 million, coke production facilities at the Kagawa Plant of ¥7,046 million, and facilities and intangible assets at certain sites of Clean Part USA of ¥3,655 million, reflecting deteriorating profitability due to the cancellation of construction plans and site closures. - FY2024MaterialisedAnnual report
「In the current consolidated fiscal year, impairment losses of ¥33,530 million were recognized and included in "Other operating expenses" in the consolidated statement of profit or loss. The principal component was the high-purity terephthalic acid production equipment of Mitsubishi Chemical Indonesia.」
Although impairment losses decreased from ¥96,782 million in the previous fiscal year to ¥33,530 million, impairment arose on PTA facilities, phenol and bisphenol A facilities, and ACH-process MMA and acrylonitrile facilities at the Hiroshima site. - FY2024-Q3MitigatedAnnual report
「Impairment losses ¥14,207 million」
Cumulative third-quarter impairment losses amounted to ¥14.207 billion, a substantial decrease from ¥88.399 billion in the same period of the previous fiscal year. Meanwhile, the company recorded impairment losses of ¥9.699 billion on PTA production facilities of Mitsubishi Chemical Indonesia. - FY2024-Q2WorsenedAnnual report
「Impairment losses ¥3,413 million」
Cumulative second-quarter impairment losses amounted to ¥3.413 billion, up from ¥2.327 billion in the same period of the previous fiscal year. Impairment arising from declining profitability at facilities and businesses continued. - FY2024-Q1MitigatedAnnual report
「Impairment losses ¥199 million」
Cumulative first-quarter impairment losses amounted to ¥199 million, down from ¥356 million in the same period of the previous fiscal year. Impairment arising from declining profitability at facilities and businesses remains, but the amount recognized decreased year on year. - FY2023WorsenedAnnual report
「The company recorded impairment losses of ¥96,782 million in the consolidated fiscal year and included them in Other operating expenses in the consolidated income statement.」
Impairment losses increased from ¥26.047 billion in the previous fiscal year to ¥96.782 billion. The main components were MMA production facilities at the Chassell plant and Medicago's vaccine production facilities and goodwill. - FY2023-Q3WorsenedAnnual report
「During the cumulative third quarter, the company recorded impairment losses of ¥88,399 million.」
Impairment losses increased substantially from ¥8.007 billion in the same period of the previous fiscal year to ¥88.399 billion. The breakdown included ¥37.512 billion on MMA production facilities at the Chassell plant and ¥48.029 billion on vaccine production facilities and related goodwill at Medicago. - FY2023-Q2MitigatedAnnual report
「Impairment losses ¥2,327 million」
Cumulative second-quarter impairment losses amounted to ¥2.327 billion, down from ¥3.622 billion in the same period of the previous fiscal year. Impairment arising from declining profitability at facilities and businesses continued. - FY2022MaterialisedAnnual report
「During the current consolidated fiscal year, the Company recognized impairment losses of ¥26,047 million, which were included under “Other operating expenses” in the consolidated statement of income. The main component was an intangible asset related to technology for developing a treatment for osteoarthritis, consisting of rights acquired under an in-license agreement during the development stage.」
Although down from ¥127,193 million in the previous fiscal year, the company recorded impairment losses of ¥26,047 million arising from declining profitability at facilities and businesses. The amount included ¥15,797 million in development assets for an osteoarthritis treatment and ¥3,349 million in steam turbine equipment, among other items. - FY2022-Q3MaterialisedAnnual report
「Following the decision to cancel the construction plan for part of the steam turbine equipment under construction at Mitsubishi Chemical UK’s Kassel plant, the entire carrying amount of the equipment under construction was written down, and an impairment loss of ¥3,349 million was recognized.」
Regarding the risk of impairment arising from deteriorating profitability at facilities and changes in the business environment, the full carrying amount of steam turbine equipment was written down following cancellation of the construction plan, resulting in an actual impairment loss of ¥3.349 billion. - FY2022-Q2MitigatedAnnual report
「Impairment loss 3,622」
Cumulative second-quarter impairment losses amounted to ¥3.622 billion, a substantial decrease from ¥87.093 billion in the same period of the previous fiscal year. The risk of impairment arising from deteriorating profitability at facilities and businesses remains, but the amount recognized during the period declined. - FY2021WorsenedAnnual report
「The company recorded impairment losses of ¥127,193 million in the consolidated fiscal year and included them in Other operating expenses in the consolidated income statement.」
Impairment losses increased from ¥48,647 million in the previous fiscal year to ¥127,193 million. The amount included ¥84,534 million in NeuroDerm's in-process research and development costs and ¥19,396 million in Beaumont plant equipment, among other items. - FY2021-Q3WorsenedAnnual report
「During the cumulative third quarter, the company recorded impairment losses of ¥107,924 million.」
Cumulative third-quarter impairment losses increased to ¥107.924 billion. In addition to ¥84.534 billion in NeuroDerm's in-process research and development costs, the company recorded ¥19.382 billion in impairment losses on Beaumont plant equipment. - FY2021-Q2WorsenedAnnual report
「During the cumulative second quarter, the company recorded impairment losses of ¥87,093 million. Profitability was expected to decline for a Parkinson's disease treatment being developed by NeuroDerm due to changes in the business environment. Following a review of the plan based on market research, the recoverable amount fell below the carrying amount, and the carrying amount of the intangible asset related to the technology, consisting of in-process research and development costs, was reduced to its recoverable amount of ¥43,272 million.」
Cumulative second-quarter impairment losses expanded to ¥87.093 billion, including ¥84.534 billion in in-process research and development costs at NeuroDerm, as impairment arose from deterioration in the business environment and declining profitability. - FY2020WorsenedAnnual report
「In the consolidated fiscal year, our group recorded impairment losses of ¥48,647 million.」
Impairment losses increased from ¥17,340 million in the previous fiscal year to ¥48,647 million. The amount included ¥16,274 million in goodwill related to the pharmaceutical ingredients business and ¥24,069 million in in-process research and development costs for MT-2271. - FY2020-Q3WorsenedAnnual report
「During the third quarter of the current consolidated fiscal year, the profitability of the healthcare formulation-materials business was expected to decline substantially due to deterioration in the business environment. Following a review of the business plan based on the current situation, recovery of the investment was no longer anticipated, and the carrying amount of the related goodwill was reduced to its recoverable amount of ¥15,525 million.」
In the pharmaceutical ingredients business in the healthcare sector, the business environment deteriorated and a substantial decline in profitability was expected, resulting in the recognition of a ¥17,037 million impairment loss on related goodwill. - FY2020-Q2MaterialisedAnnual report
「Impairment losses ¥1,861 million」
The company also recorded impairment losses of ¥1.861 billion during the cumulative second quarter, and impairment arising from deteriorating profitability at facilities and changes in the business environment continued. - FY2020-Q1MaterialisedAnnual report
「Impairment loss 960」
The company recorded impairment losses of ¥960 million during the cumulative first quarter, arising from deteriorating profitability at facilities and other assets and changes in the business environment. - FY2019WorsenedAnnual report
「Non-recurring items for the consolidated fiscal year resulted in a loss of ¥19.2 billion, due to impairment losses of ¥11.8 billion, losses on the disposal and sale of fixed assets of ¥8.5 billion and other items.」
Impairment losses increased from ¥12.062 billion in the previous fiscal year to ¥17.340 billion. The company also recorded ¥5.271 billion in impairment losses on pharmaceutical research facilities associated with the closure of Mitsubishi Tanabe Pharma's Toda site. - FY2019-Q3MaterialisedAnnual report
「Impairment loss 2,848」
The company also recorded impairment losses of ¥2.848 billion during the cumulative third quarter, and impairment arising from deteriorating profitability at facilities and changes in the business environment continued. - FY2019-Q2MaterialisedAnnual report
「Impairment loss 1,028」
The company also recorded impairment losses of ¥1.028 billion during the cumulative second quarter, and impairment arising from deteriorating profitability at facilities and changes in the business environment continued. - FY2019-Q1MaterialisedAnnual report
「Impairment losses ¥848 million」
The company recorded impairment losses of ¥848 million during the cumulative first quarter, and impairment arising from deteriorating profitability at facilities and changes in the business environment continued. - FY2018MaterialisedAnnual report
「Non-recurring items for the consolidated fiscal year resulted in a loss of ¥24.8 billion, due to impairment losses of ¥9.7 billion, losses on the disposal and sale of fixed assets of ¥5.6 billion and other items, representing a ¥14.1 billion reduction in loss from the previous consolidated fiscal year.」
Although impairment losses decreased from the previous fiscal year, the company recorded a total of ¥12.062 billion in impairment losses on property, plant and equipment and intangible assets during the fiscal year. - FY2018-Q3MaterialisedAnnual report
「Impairment losses ¥6,250 million」
The company also recorded impairment losses of ¥6.250 billion during the cumulative third quarter, indicating that deteriorating profitability at petrochemical and materials facilities and related impairment continued. - FY2018-Q2MaterialisedAnnual report
「Impairment losses ¥1,152 million」
The company also recorded impairment losses of ¥1,152 million during the cumulative second quarter, indicating that deteriorating profitability at petrochemical and materials facilities and related impairment continued. - FY2017MaterialisedAnnual report
「In the consolidated fiscal year, the company recognized impairment losses on production facilities for polytetramethylene ether glycol, high-performance film production facilities and other assets, against a backdrop of changes in the business environment and sluggish sales volumes.」
Impairment losses for the fiscal year totaled ¥16.822 billion, including ¥3.121 billion on polytetramethylene ether glycol facilities in China and ¥3.017 billion on high-performance film facilities. - FY2017-Q3MaterialisedAnnual report
「During the nine months ended the third quarter of the current consolidated fiscal year, ¥9,997 million was recognized as an impairment loss under “Other operating expenses” in the condensed quarterly consolidated statement of income.」
During the cumulative third quarter, impairment losses of ¥9,997 million arose on production facilities for polytetramethylene ether glycol, high-performance film production facilities and other assets, against a backdrop of changes in the business environment and sluggish sales volumes. - FY2017-Q2MaterialisedAnnual report
「During the six months ended the second quarter of the current consolidated fiscal year, ¥7,957 million was recognized as an impairment loss under “Other operating expenses” in the condensed quarterly consolidated statement of income.」
Impairment losses arose on production facilities for polytetramethylene ether glycol in China totaling ¥3,121 million and high-performance film production facilities totaling ¥3,017 million, among others, due to changes in the business environment and sluggish sales volumes. - FY2017-Q1MaterialisedAnnual report
「Impairment loss 874」
The company recorded an impairment loss of ¥874 million (¥0.874 billion) in the first quarter. This indicates that impairment arising from deteriorating asset profitability and other factors continued from the previous fiscal year. - FY2016MaterialisedAnnual report
「In the consolidated fiscal year, the company recorded ¥78,992 million in impairment losses as extraordinary losses.」
The company recorded impairment losses of ¥78.992 billion in the fiscal year, mainly on terephthalic acid production facilities, due to poor performance and reduced prospects for recovery in the business environment.